Biotech Stocks See Major Selling Pressure
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
UPDATE: BMO Capital Upgrades Biogen (BIIB) to Outperform
March 6, 2014 6:38 AM EST(Updated - March 6, 2014 12:10 PM EST)
BMO Capital upgraded Biogen (NASDAQ: BIIB) from Market Perform to Outperform with a price target of $422. Analyst Jim Birchenough, M.D. sees too many transformational opportunities to ignore.
The firm conducted an extensive pipeline review, and updated their financial model to reflect nearer-term opportunities for new product growth with ELOCTATE and... More



